此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

术中使用 20% 白蛋白联合乳酸林格液与热腹腔化疗减瘤手术中乳酸林格液的疗效:随机开放标签临床试验方案 (ALBUCHIP)

2026年9月24日 更新者:Assistance Publique - Hôpitaux de Paris

评估血管重建功效 Par de l'ALBUmine Humaine 20% + Ringer Lactate 与 Ringer Lactate Seul Chez Les Members opérés Par cytoréduction Avec CHimiothérapie Intrapéritonéale hyPerthermique

Introduction Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered as the standard of care for the treatment of peritoneal metastases. Cytoreductive surgery with HIPEC is characterized by large intra operative fluid shift secondary to surgical resection, peritoneal inflammation and capillary shifts, requesting high volume of intra operative fluid therapy. Previous studies found a strong association between intra operative hypovolemia or volume overload with post operative outcomes. Albumin as an intravenous fluid has been widely studied in critical ill patients, but evaluation of its efficacy during major surgery on post operative clinical outcomes are lacking. We hypothesize that a reduction of intra operative crystalloid volume infusion by using 20% albumin during CRS with HIPEC could improve patients' prognosis. The aim of this study will be to assess the efficacy of 20% albumin combined with Ringer Lactate versus Ringer Lactate for fluid therapy during CRS with HIPEC on post operative outcome at 28 day.

Methods and analysis The study protocol has been designed and written in accordance with the Prospective randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.

Recruitment, randomisation and allocation Information on the study and screening of patients will be conducted during the consultation of anaesthesia (= selection visit), 2 months at 3 days before the surgery. Information notice and consent form will be delivered. The day before the surgery, anaesthesiologist who will conduct the pre anaesthetic visit will be able to include patients in the study (=inclusion visit). Randomisation will be done at the inclusion visit after information and signature of consent form of voluntary patients. A randomization number will be assigned. The 1:1 randomisation will be centralized via an online interface ensuring secret group assignment, and based on predefined randomisation lists with variable-size permutation blocks, stratified by center. Randomisation will be accomplished using a computer-generated random sequence.

Randomized Open, Blinded endpoint (PROBE) design. This study is a randomised, comparative, controlled, prospective, open-label, with parallel group and multicentre clinical trial.

Intervention

  • 20% Albumin + Ringer Lactate group (intervention group) Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
  • Control group Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.

Outcome measures The primary outcome will be the Comprehensive Complication Index (CCI score) at day 28 after CRS with HIPEC. Secondary outcomes are mortality at day 28, CCI score at day 7, volume of intra operative and post operative (48h) post operative fluid therapy, cumulated incidence of surgical post operative complications, cumulated incidence of medical post operative complications, need for mechanical ventilation, renal replacement therapy between surgery and day 28, SOFA score variation between pre operative period and 48h after surgery, number of days alive out of intensive care unit and out of hospital until day 28

Sample size calculation To ensure a power of 80%, a number of patients 130 (65 patients by group) will be necessary with a reduction of 13.6 (SD 24) points of the CCI score at day 28 in the intervention group. Because of a risk of neoplastic evolution between anaesthetic consultation and randomisation (10% of early cancellation), a total of 146 patients (73 by group) will be included in the study.

Discussion In summary, ALBUCHIP study will be the first randomized clinical trial assessing efficacy of intraoperative use of 20% albumin combined with Ringer Lactate versus Ringer Lactate during CRS with HIPEC. Results yielded from this study will be helpful for vascular filling during CRS with HIPEC but, thanks to ancillary studies, to improve pathophysiological understanding of this surgery.

研究概览

研究类型

介入性

注册 (估计的)

140

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Lyon、法国
        • 招聘中
        • Hôpital Lyon Sud Pierre Bénite
        • 接触:
      • Montpellier、法国
        • 招聘中
        • Institut régional du Cancer de Montpellier
        • 接触:
      • Paris、法国、75013
        • 招聘中
        • La Pitié Salpetriere hospital
        • 接触:
      • Paris、法国
        • 招聘中
        • Lariboisière hospital
        • 接触:
      • Paris、法国
        • 招聘中
        • Saint Louis hospital
        • 接触:
      • Reims、法国
        • 招聘中
        • Robert Debré hospital
        • 接触:
      • Strasbourg、法国
      • Villejuif、法国

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male and female patients aged 18 years old and older
  • Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis (from gynaecological or digestive origin)
  • Patient volunteer for the study and provided written informed consent
  • Patient affiliated to the French Health Insurance

Exclusion Criteria:

  • Adults >75 years old
  • Functional status rendering the patient ineligible for cytoreduction with CHIP (ECOG > 2 or Karnofsky index < 75)
  • Pre-existing preoperative conditions affecting albuminemia (hepatic cirrhosis, nephrotic syndrome, exudative enteropathy, malnutrition)
  • Severe preoperative hypoalbuminemia (albuminemia < 20 g/L)
  • History of chronic left heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction < 40%)
  • Patients at high risk of perioperative and postoperative pulmonary complications (atelectasis, significant pleural effusions)
  • Significant ascites with preoperative respiratory repercussions
  • Uncontrolled diabetes (HbA1c > 8.5%)
  • Allergy to exogenous human albumin and its excipients.
  • Contraindication to the administration of Ringer's lactate (history of allergy)
  • Hyperkalemia > 6.0 mmol/L
  • Hypercalcemia (total calcium > 2.60 mmol/L)
  • Chronic use of digitalis and hyperkalemic diuretics
  • Pregnancy, breastfeeding
  • Known preoperative renal failure (GFR < 30 mL/min/1.73m2 or extrarenal purification)
  • Recent brain trauma < 6 months (traumatic, ischemic, or hemorrhagic)
  • Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable
  • Patient deprived of liberty
  • Patient under guardianship or curatorship

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:20% Albumin + Ringer Lactate group

Per-operative fluid therapy consisting in Ringer Lactate combined with 20% albumin. Patients will receive a bolus of 3 mL/kg on one hour of 20% albumin from anaesthetic induction. Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.

Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.

有源比较器:Control group

Ringer Lactate for intra operative fluid management based on the latest scientific recommendations. As the the study is an open labelled randomized clinical trial, placebo use is not planned.

Ringer lactate

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Comprehensive Complication Index score
大体时间:At day 28

The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery.

The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death

At day 28

次要结果测量

结果测量
措施说明
大体时间
术中和术后液体治疗量
大体时间:手术后48小时
手术后48小时
手术术后并发症的累积发生率
大体时间:截至第 28 天
截至第 28 天
离开重症监护室的存活天数
大体时间:截至第 28 天
截至第 28 天
出院存活天数
大体时间:截至第 28 天
截至第 28 天
感染性并发症的发生率
大体时间:截至第28天
截至第28天
医疗并发症的发生率
大体时间:截至第28天
截至第28天
重症监护病房累计死亡率
大体时间:截至第28天
截至第28天
院内死亡累积发生率
大体时间:截至第28天
截至第28天
血管加压药使用天数
大体时间:至第28天
至第28天
对白蛋白出现过敏并发症的患者比例
大体时间:第 133 天
第 133 天
Comprehensive Complication Index score
大体时间:At day 7

The Comprehensive Complication Index (CCI) is a score ranging from 0 to 100, calculated using all complications and their treatment after abdominal surgery.

The CCI is that it is a linear scale ranging from 0 to 100, where 100 represents death

At day 7
Number of days under mechanical ventilation outside the operating room
大体时间:Up to day 28

Between surgery and day 28

Up to day 28
Number of days under renal replacement therapy
大体时间:Up to day 28

Between surgery and day 28

Up to day 28
Sequential organ failure assessment (SOFA) score variation
大体时间:48 hours after surgery

Between pre operative period and 48h after surgery

48 hours after surgery
SOFA score
大体时间:At day 28

Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function

At day 28

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月3日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2024年4月2日

首先提交符合 QC 标准的

2024年4月2日

首次发布 (实际的)

2024年4月8日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2025年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅